Cenobamate not checked
SK Life Science, Inc. · YKP3089 · YKP3089C045
FollowEvery change as it happens, and a Monday email
Trials
4 active
17 in total · 4 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The 100 mg/ day Treatment Period includes a 6-week Titration Phase and a 26-week Maintenance Phase. During the Titration Phase subjects will be treated with cenobamate 12.5 mg/day for two weeks, 25 mg/day for two weeks and 50 mg/day for two weeks. Subjects tolerating cenobamate at the end of the Titration Phase will continue treatment with 100 mg/day in the Maintenance Phase for 26 weeks. If the…”In the company’s words, NCT06453213 on ClinicalTrials.gov
- Main trialPhase 4
- “Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagnosed or recurrent POS/focal onset epilepsy.”In the company’s words, NCT06453213 on ClinicalTrials.gov
- Other names
- YKP3089 · YKP3089C045 · Xcopri
Other drugs for Focal Onset Seizure
- BHV-7000Biohaven · Phase 2/3
- ElsunersenPraxis Precision Medicines · Phase 3
- LP352Longboard Pharmaceuticals · Phase 3
- EverolimusNovartis Pharmaceuticals · Phase 3
- CarisbamateSK Life Science, Inc. · Phase 3
- Clemizole HClEpygenix · Phase 3
Coming up4
- 31 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Jan 2027Phase 2 trial completes · ClinicalTrials.gov
- 26 May 2027Phase 4 trial completes · ClinicalTrials.gov
- 30 Mar 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials17
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 26 May 2027 | Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy | |
| Phase 3Recruiting | 31 Jan 2027 | ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures. | |
| Phase 3Recruiting | 30 Mar 2028 | A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds | |
| Phase 2Recruiting | 31 Jan 2027 | Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures | |
| Phase 3Completed | 31 Mar 2021 | Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures | |
| Phase 3Completed | 16 Feb 2024 | Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS | |
| Phase 3Completed | 26 May 2025 | Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures | |
| Phase 3Completed | 10 Jun 2026 | Cenobamate Open-Label Extension Study for YKP3089C025 | |
| Phase 3Completed | 2 Oct 2026 | Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures | |
| Phase 2Completed | Jun 2013 | Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures | |
| Phase 2Completed | 5 Apr 2021 | A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures | |
| Phase 1Completed | 3 Jul 2017 | Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions | |
| Phase 1Completed | 18 Nov 2017 | A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users | |
| Phase 1Completed | 17 May 2021 | Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet | |
| Phase 1Completed | 15 Nov 2022 | Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment | |
| Phase 1Completed | 28 Jan 2023 | A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally | |
| Phase 1Completed | 6 Nov 2025 | Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026